Vanderbilt University

Michael Matheny of Vanderbilt University presents 'Opportunities and Challenges in the Use of Large Language Models for Postmarketing Surveillance of Medical Products' at PCT Grand Rounds on December 6, 2024, at 1:00 pm eastern.

USF Health and Weill Cornell Medicine published the first version of their clinically validated voice dataset on an AI platform, aiming to diagnose diseases like cancer and depression through voice analysis. The dataset includes over 12,500 recordings from 306 participants and will be expanded to 10,000 voices by the end of a four-year $14 million project. The data is standardized and includes respiratory, voice, and speech tasks, crucial for validating voice algorithms and developing new diagnostic methods.

Vanderbilt University receives up to $46 million from ARPA-H to develop a vaccine against all alphaviruses, led by Jens Meiler and a multidisciplinary team. The project aims to use advanced technologies like computational modeling and AI for long-lasting protection, addressing a critical gap in global health.

KarXT, a new schizophrenia drug targeting muscarinic receptors, has sparked excitement in psychiatric medicine, with several similar drugs in development. However, the failure of a highly anticipated muscarinic drug, emraclidine, in a trial raises questions about the future of this approach. KarXT's success has revived interest in muscarinic drugs, but the development process remains challenging and uncertain.

The Advanced Ablation Catheters Pipeline Report 2024, added to ResearchAndMarkets.com's offering, provides comprehensive details on pipeline products, clinical trials, and key companies involved in advanced ablation catheters development.

Exploring new therapeutic horizons for PCOS, focusing on potential treatments targeting CYP11A1 and CYP17A1 enzymes, with artemisinin showing promise as a CYP11A1 degrader. Considerations include the impact on progesterone levels and the need for tailored therapies for different PCOS subtypes.

Vanderbilt University's Dare to Grow campaign surpassed its $3.2 billion goal 20 months early, supported by 138,500 donors. The campaign has funded scholarships, research, and facilities, including the Roberts Academy and Dyslexia Center, Dialogue Vanderbilt, and Vandy United. Chancellor Daniel Diermeier emphasized the campaign's role in Vanderbilt's ambition to become the Great University of the 21st Century.

Cumberland Pharmaceuticals announced FDA granted Orphan Drug and Rare Pediatric Disease Designations to Ifetroban for treating cardiomyopathy in Duchenne muscular dystrophy (DMD). The FIGHT DMD™ trial, a Phase II study, is investigating Ifetroban's safety and efficacy in DMD patients, with results expected later this year.

HTAN webinar features Li Ding, Ken Lau, and Shannon Hughes discussing cancer atlas integration, spatial technologies, and evolutionary principles in cancer research, moderated by Alexia-Ileana Zaromytidou.

Dr. Tim Jancelewicz, co-principal investigator, leads an $11.4 million, multi-institutional clinical trial to study the efficacy of nitric oxide in treating newborns with congenital diaphragmatic hernia (CDH). The NoNO Trial, funded by the NIH, involves 19 institutions and aims to determine if nitric oxide reduces the need for invasive care like ECMO. The trial also explores barriers to de-implementation of nitric oxide and its continued use despite lack of supporting evidence.